Healthcare provider profile · identity verified

Jennifer Mitchell, MD

Family Practice · SALINAS, CA · NPI 1346629177

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	363	141
Losartan Potassium	Losartan Potassium	224	88
Amlodipine Besylate	Amlodipine Besylate	218	96
Omeprazole	Omeprazole	178	72
Lisinopril	Lisinopril	147	65
Metformin Hcl	Metformin Hcl	147	58
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	131	56
Levothyroxine Sodium	Levothyroxine Sodium	114	46
Rosuvastatin Calcium	Rosuvastatin Calcium	114	45
Simvastatin	Simvastatin	105	39
Hydrochlorothiazide	Hydrochlorothiazide	104	38
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	38
Albuterol Sulfate Hfa	Albuterol Sulfate	87	51
Ibuprofen	Ibuprofen	87	30
Gabapentin	Gabapentin	85	43
Metformin Hcl Er	Metformin Hcl	83	29
Alendronate Sodium	Alendronate Sodium	81	34
Glipizide	Glipizide	81	38
Atenolol	Atenolol	80	30
Trazodone Hcl	Trazodone Hcl	78	33
Potassium Chloride	Potassium Chloride	67	25
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	21
Meloxicam	Meloxicam	59	28
Lactulose	Lactulose	53	12
Ozempic	Semaglutide	48	suppressed
Terazosin Hcl	Terazosin Hcl	48	20
Tramadol Hcl	Tramadol Hcl	44	25
Furosemide	Furosemide	43	24
Fluoxetine Hcl	Fluoxetine Hcl	42	13
Metoprolol Tartrate	Metoprolol Tartrate	40	16
Tamsulosin Hcl	Tamsulosin Hcl	40	17
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	38	21
Carvedilol	Carvedilol	36	12
Pantoprazole Sodium	Pantoprazole Sodium	36	19
Prednisone	Prednisone	34	22
Triamcinolone Acetonide	Triamcinolone Acetonide	34	20
Allopurinol	Allopurinol	28	13
Duloxetine Hcl	Duloxetine Hcl	28	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	27	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	27	suppressed
Humulin N	Insulin Nph Human Isophane	26	11
Morphine Sulfate Er	Morphine Sulfate	26	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	26	suppressed
Lidocaine	Lidocaine	25	suppressed
Spiriva Respimat	Tiotropium Bromide	25	suppressed
Benazepril Hcl	Benazepril Hcl	24	suppressed
Montelukast Sodium	Montelukast Sodium	24	11
Sertraline Hcl	Sertraline Hcl	24	14
Alvesco	Ciclesonide	23	12
Azelastine Hcl	Azelastine Hcl	23	suppressed
Estradiol	Estradiol	23	suppressed
Lorazepam	Lorazepam	21	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	20	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	19	suppressed
Clopidogrel	Clopidogrel Bisulfate	19	suppressed
Jardiance	Empagliflozin	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	18	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	18	suppressed
Glipizide Er	Glipizide	17	suppressed
Hydrocortisone	Hydrocortisone	17	13
Ciclopirox	Ciclopirox	16	suppressed
Ondansetron Odt	Ondansetron	16	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	16	suppressed
Ezetimibe	Ezetimibe	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Acyclovir	Acyclovir	14	suppressed
Famotidine	Famotidine	14	suppressed
Finasteride	Finasteride	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Baclofen	Baclofen	12	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	12	12
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Colchicine	Colchicine	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error